Log In
Print
BCIQ
Print
Print this Print this
 

E2609

  Manage Alerts
Collapse Summary General Information
Company Eisai Co. Ltd.
DescriptionBeta-site APP-cleaving enzyme (BACE) inhibitor
Molecular Target
Mechanism of ActionBeta-site APP-cleaving enzyme 1 (BACE1) inhibitor
Therapeutic Modality 
Latest Stage of DevelopmentPhase I
Standard IndicationAlzheimer's disease (AD)
Indication DetailsTreat Alzheimer's disease (AD)
Regulatory Designation

Partner

Biogen Idec Inc.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today